Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 2/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 5/20 | 0.36 |
| ▸ | JAK1 | P23458 | 7/20 | 0.36 |
| ▸ | JAK2 | O60674 | 6/20 | 0.36 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.35 |
| ▸ | JAK3 | P52333 | 2/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | TYK2 | P29597 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17177171 | 0.91 | KDM4E (0.41) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL14421728 | 0.84 | KDM4E (0.42) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL12424701 | 0.84 | KDM4E (0.42) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL12384689 | 0.82 | ALDH1A1 (0.41) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL12384796 | 0.82 | MEN1 (0.41) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL19568021 | 0.81 | KDM4E (0.43) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL14417884 | 0.81 | KDM4E (0.54) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL14147668 | 0.78 | ALDH1A1 (0.40) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL1894338 | 0.77 | ATM (0.50) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL1899746 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461328-B2 | Tricyclic heterocyclic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-7268150-B2 | 2-cyano-4-fluoropyrrolidine derivative or its salt | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2007-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CCNY, CCNA1, CCNA2 | KDM4E 2333/4885MEN1 298/4885ALDH1A1 1168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.